title: Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
abstract: BACKGROUND
  The best way to initiate dopaminergic therapy for early Parkinson disease remains unclear.
  
  
  OBJECTIVE
  To compare initial treatment with pramipexole vs levodopa in early Parkinson disease, followed by levodopa supplementation, with respect to the development of dopaminergic motor complications, other adverse events, and functional and quality-of-life outcomes.
  
  
  METHODS
  Multicenter, parallel-group, double-blind, randomized controlled trial.
  
  
  METHODS
  Academic movement disorders clinics at 22 sites in the United States and Canada.
  
  
  METHODS
  Patients with early Parkinson disease (N = 301) who required dopaminergic therapy to treat emerging disability, enrolled between October 1996 and August 1997 and observed until August 2001.
  
  
  METHODS
  Subjects were randomly assigned to receive 0.5 mg of pramipexole 3 times per day with levodopa placebo (n = 151) or 25/100 mg of carbidopa/levodopa 3 times per day with pramipexole placebo (n = 150). Dosage was escalated during the first 10 weeks for patients with ongoing disability. Thereafter, investigators were permitted to add open-label levodopa or other antiparkinsonian medications to treat ongoing or emerging disability.
  
  
  METHODS
  Time to the first occurrence of dopaminergic complications: wearing off, dyskinesias, on-off fluctuations, and freezing; changes in the Unified Parkinson's Disease Rating Scale and quality-of-life scales; and adverse events.
  
  
  RESULTS
  Initial pramipexole treatment resulted in a significant reduction in the risk of developing dyskinesias (24.5% vs 54%; hazard ratio, 0.37; 95% confidence interval [CI], 0.25-0.56; P<.001) and wearing off (47% vs 62.7%; hazard ratio, 0.68; 95% CI, 0.49-0.63; P =.02). Initial levodopa treatment resulted in a significant reduction in the risk of freezing (25.3% vs 37.1%; hazard ratio, 1.7; 95% CI, 1.11-2.59; P =.01). By 48 months, the occurrence of disabling dyskinesias was uncommon and did not significantly differ between the 2 groups. The mean improvement in the total Unified Parkinson's Disease Rating Scale score from baseline to 48 months was greater in the levodopa group than in the pramipexole group (2 +/- 15.4 points vs -3.2 +/- 17.3 points, P =.003). Somnolence (36% vs 21%, P =.005) and edema (42% vs 15%, P<.001) were more common in pramipexole-treated subjects than in levodopa-treated subjects. Mean changes in quality-of-life scores did not differ between the groups.
  
  
  CONCLUSIONS
  Initial treatment with pramipexole resulted in lower incidences of dyskinesias and wearing off compared with initial treatment with levodopa. Initial treatment with levodopa resulted in lower incidences of freezing, somnolence, and edema and provided for better symptomatic control, as measured by the Unified Parkinson's Disease Rating Scale, compared with initial treatment with pramipexole. Both options resulted in similar quality of life. Levodopa and pramipexole both appear to be reasonable options as initial dopaminergic therapy for Parkinson disease, but they are associated with different efficacy and adverse-effect profiles.
authors.affiliation: Department of Neurology, University of Rochester, 1351 Mt. Hope Avenue, Suite 220, Rochester, NY 14620, USA. robert.holloway@ctcc.rochester.edu
authors.forename: Robert G
authors.initials: RG
authors.lastname: Holloway
authors.forename: Ira
authors.initials: I
authors.lastname: Shoulson
authors.forename: Stanley
authors.initials: S
authors.lastname: Fahn
authors.forename: Karl
authors.initials: K
authors.lastname: Kieburtz
authors.forename: Anthony
authors.initials: A
authors.lastname: Lang
authors.forename: Kenneth
authors.initials: K
authors.lastname: Marek
authors.forename: Michael
authors.initials: M
authors.lastname: McDermott
authors.forename: John
authors.initials: J
authors.lastname: Seibyl
authors.forename: William
authors.initials: W
authors.lastname: Weiner
authors.forename: Bruno
authors.initials: B
authors.lastname: Musch
authors.forename: Cornelia
authors.initials: C
authors.lastname: Kamp
authors.forename: Mickie
authors.initials: M
authors.lastname: Welsh
authors.forename: Aileen
authors.initials: A
authors.lastname: Shinaman
authors.forename: Rajesh
authors.initials: R
authors.lastname: Pahwa
authors.forename: Lynn
authors.initials: L
authors.lastname: Barclay
authors.forename: Jean
authors.initials: J
authors.lastname: Hubble
authors.forename: Peter
authors.initials: P
authors.lastname: LeWitt
authors.forename: Janis
authors.initials: J
authors.lastname: Miyasaki
authors.forename: Oksana
authors.initials: O
authors.lastname: Suchowersky
authors.forename: Mark
authors.initials: M
authors.lastname: Stacy
authors.forename: David S
authors.initials: DS
authors.lastname: Russell
authors.forename: Blair
authors.initials: B
authors.lastname: Ford
authors.forename: John
authors.initials: J
authors.lastname: Hammerstad
authors.forename: David
authors.initials: D
authors.lastname: Riley
authors.forename: David
authors.initials: D
authors.lastname: Standaert
authors.forename: Frederick
authors.initials: F
authors.lastname: Wooten
authors.forename: Stewart
authors.initials: S
authors.lastname: Factor
authors.forename: Joseph
authors.initials: J
authors.lastname: Jankovic
authors.forename: Farah
authors.initials: F
authors.lastname: Atassi
authors.forename: Roger
authors.initials: R
authors.lastname: Kurlan
authors.forename: Michel
authors.initials: M
authors.lastname: Panisset
authors.forename: Ali
authors.initials: A
authors.lastname: Rajput
authors.forename: Robert
authors.initials: R
authors.lastname: Rodnitzky
authors.forename: Cliff
authors.initials: C
authors.lastname: Shults
authors.forename: Giselle
authors.initials: G
authors.lastname: Petsinger
authors.forename: Cheryl
authors.initials: C
authors.lastname: Waters
authors.forename: Ronald
authors.initials: R
authors.lastname: Pfeiffer
authors.forename: Kevin
authors.initials: K
authors.lastname: Biglan
authors.forename: Leona
authors.initials: L
authors.lastname: Borchert
authors.forename: Amy
authors.initials: A
authors.lastname: Montgomery
authors.forename: Laura
authors.initials: L
authors.lastname: Sutherland
authors.forename: Carolyn
authors.initials: C
authors.lastname: Weeks
authors.forename: Maryan
authors.initials: M
authors.lastname: DeAngelis
authors.forename: Elspeth
authors.initials: E
authors.lastname: Sime
authors.forename: Susan
authors.initials: S
authors.lastname: Wood
authors.forename: Carol
authors.initials: C
authors.lastname: Pantella
authors.forename: Mary
authors.initials: M
authors.lastname: Harrigan
authors.forename: Barbara
authors.initials: B
authors.lastname: Fussell
authors.forename: Sandra
authors.initials: S
authors.lastname: Dillon
authors.forename: Barbara
authors.initials: B
authors.lastname: Alexander-Brown
authors.forename: Pamela
authors.initials: P
authors.lastname: Rainey
authors.forename: Marsha
authors.initials: M
authors.lastname: Tennis
authors.forename: Elke
authors.initials: E
authors.lastname: Rost-Ruffner
authors.forename: Diane
authors.initials: D
authors.lastname: Brown
authors.forename: Sharon
authors.initials: S
authors.lastname: Evans
authors.forename: Debra
authors.initials: D
authors.lastname: Berry
authors.forename: Jean
authors.initials: J
authors.lastname: Hall
authors.forename: Theresa
authors.initials: T
authors.lastname: Shirley
authors.forename: Judith
authors.initials: J
authors.lastname: Dobson
authors.forename: Deborah
authors.initials: D
authors.lastname: Fontaine
authors.forename: Brenda
authors.initials: B
authors.lastname: Pfeiffer
authors.forename: Alicia
authors.initials: A
authors.lastname: Brocht
authors.forename: Susan
authors.initials: S
authors.lastname: Bennett
authors.forename: Susan
authors.initials: S
authors.lastname: Daigneault
authors.forename: Karen
authors.initials: K
authors.lastname: Hodgeman
authors.forename: Carolynn
authors.initials: C
authors.lastname: O'Connell
authors.forename: Tori
authors.initials: T
authors.lastname: Ross
authors.forename: Karen
authors.initials: K
authors.lastname: Richard
authors.forename: Arthur
authors.initials: A
authors.lastname: Watts
mesh_terms: D000368:Aged; D052160:Benzothiazoles; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D000077487:Pramipexole; D016016:Proportional Hazards Models; D011788:Quality of Life / Q000523:psychology; D012720:Severity of Illness Index; D013844:Thiazoles / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D052160:Benzothiazoles; D013844:Thiazoles; D007980:Levodopa; D000077487:Pramipexole